Compare DHX & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHX | IPSC |
|---|---|---|
| Founded | 1991 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.3M | 248.1M |
| IPO Year | 2007 | 2021 |
| Metric | DHX | IPSC |
|---|---|---|
| Price | $4.40 | $1.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $6.75 | $4.75 |
| AVG Volume (30 Days) | 207.1K | ★ 968.6K |
| Earning Date | 11-04-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $127,826,000.00 | $109,164,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.24 | N/A |
| P/E Ratio | $31.00 | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $1.44 | $0.44 |
| 52 Week High | $5.19 | $2.97 |
| Indicator | DHX | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 42.07 | 55.34 |
| Support Level | $3.80 | $1.29 |
| Resistance Level | $5.03 | $1.75 |
| Average True Range (ATR) | 0.29 | 0.16 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 23.97 | 73.75 |
DHI Group Inc is a provider of software products, online tools, and services that deliver career marketplaces to candidates and employers in the United States. The company operates through two reportable segments: ClearanceJobs and Dice. Its brands enable recruiters and hiring managers to search, match, and connect with skilled technologists, particularly in technology and active government security clearance, while professionals find job opportunities, job advice, and personalized data. ClearanceJobs connects security-cleared professionals with employers in a secure environment and supports engagement through messaging and live video. Dice, which generates maximum revenue, is a destination for technology and engineering talent, offering job postings across a range of technology roles.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.